Sarepta Therapeutics (SRPT) Says Exondys-51 List Price to be $300K/Year
- Euro and global stocks hold Italy-related gains ahead of ECB
- GoDaddy (GDDY) to Acquire Host Europe Group in ~$1.8B Deal
- Twitter (TWTR) 'Takeover Money' Moves On as 'Trump Money' Moves In
- Amazon (AMZN) Could Open Over 2,000 Brick-and Mortar Groceries if Tests Succeed - DJ; Kroger (KR) on Watch
- Evercore ISI Upgrades Netflix (NFLX) to Hold; Competition Gaining Little Traction
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Sarepta Therapeutics (NASDAQ: SRPT) Says Exondys-51 List Price to be $300K/Year
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AstraZeneca (AZN) Announces Significant Data from Tagrisso AURA3 Trial in NSCLC
- Noble Midstream Partners LP (NBLX) Offers Q4 Outlook Ahead of Wells Fargo Conference
- Bank of America (BAC), Peers Show Strength on Market Open (GS) (WFC)
Create E-mail Alert Related CategoriesCorporate News, Hot Corp. News, Momentum Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!